Oestreicher Nina, Lehman Constance D, Seger Deborah J, Buist Diana S M, White Emily
Pharmaceutical Outcome Research and Policy Program, University of Washington School of Pharmacy, Center for Cost & Outcomes Research, Seattle, WA 98195, USA.
AJR Am J Roentgenol. 2005 Feb;184(2):428-32. doi: 10.2214/ajr.184.2.01840428.
The objective of this study was to determine the potential added contribution of clinical breast examination (CBE) to invasive breast cancer detection in a mammography screening program, by categories of age and breast density.
We prospectively followed 61,688 women aged 40 years or older who had undergone at least one screening examination with mammography and CBE between January 1, 1996, and December 31, 2000, for 1 year after their mammogram for invasive cancer. We computed the incremental sensitivity, specificity, and positive predictive value of CBE over mammography alone for combinations of age and breast density (predominantly fatty or dense).
Mammography sensitivity was 78% and combined mammography-CBE sensitivity was 82%, thus CBE detected an additional 4% of invasive cancers. CBE detected a minority of invasive cancers compared with mammography for all age groups and all breast densities. Sensitivity increased from adding CBE to screening mammography for all ages, from 6.8% in women ages 50-59 with dense breasts to 1.8% in women ages 60-69 years with fatty breasts. CBE generally added incrementally more to sensitivity among women with dense breasts. Specificity and positive predictive value declined when CBE was used in conjunction with mammography, and this decrement was more pronounced in women with dense breasts.
CBE had modest incremental benefit to invasive cancer detection over mammography alone in a screening program, but also led to greater risk of false-positive results. These risks and benefits were greater in women with dense breasts. The balance of risks and benefits must be weighed carefully when evaluating the inclusion of CBE in a screening examination.
本研究的目的是通过年龄和乳腺密度类别,确定临床乳腺检查(CBE)在乳腺钼靶筛查项目中对浸润性乳腺癌检测的潜在额外贡献。
我们前瞻性地跟踪了61688名年龄在40岁及以上的女性,她们在1996年1月1日至2000年12月31日期间至少接受过一次乳腺钼靶和CBE筛查,在其乳腺钼靶检查后1年内观察浸润性癌症情况。我们计算了CBE相对于单独乳腺钼靶检查在年龄和乳腺密度(主要为脂肪型或致密型)组合情况下的增量敏感性、特异性和阳性预测值。
乳腺钼靶检查的敏感性为78%,乳腺钼靶与CBE联合检查的敏感性为82%,因此CBE检测出了另外4%的浸润性癌症。在所有年龄组和所有乳腺密度情况下,与乳腺钼靶检查相比,CBE检测出的浸润性癌症占少数。对于所有年龄段,将CBE添加到乳腺钼靶筛查中可提高敏感性,从50 - 59岁致密乳腺女性的6.8%到60 - 69岁脂肪型乳腺女性的1.8%。CBE通常在致密乳腺女性中对敏感性的增量更大。当CBE与乳腺钼靶检查联合使用时,特异性和阳性预测值下降,并且这种下降在致密乳腺女性中更为明显。
在筛查项目中,CBE相对于单独的乳腺钼靶检查对浸润性癌症检测有适度的增量益处,但也导致假阳性结果的风险增加。这些风险和益处在致密乳腺女性中更大。在评估将CBE纳入筛查检查时,必须仔细权衡风险和益处的平衡。